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ABSTRACT
Clinical practice guidelines published by the European Society of Cardiology and the 
American College of Cardiology/American Heart Association summarize the available 
evidence and provide recommendations for health professionals to enable appropriate 
clinical decisions and improve clinical outcomes for patients with acute myocardial 
infarction (AMI). However, most current guidelines are based on studies in non-Asian 
populations in the pre-percutaneous coronary intervention (PCI) era. The Korea Acute 
Myocardial Infarction Registry is the first nationwide registry to document many aspects of 
AMI from baseline characteristics to treatment strategies. There are well-organized ongoing 
and published randomized control trials especially for antiplatelet therapy among Korean 
patients with AMI. Here, members of the Task Force of the Korean Society of Myocardial 
Infarction review recent published studies during the current PCI era, and have summarized 
the expert consensus for the pharmacotherapy of AMI.
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INTRODUCTION
Although the introduction of reperfusion strategy and effective medications for secondary 
prevention have improved the clinical outcomes for patients with acute myocardial infarction 
(AMI), the mortality and re-hospitalization rates after AMI remain high.1-3) Guidelines for 
AMI published by the European Society of Cardiology (ESC) and the American College of 
Cardiology/American Heart Association (ACC/AHA) summarize available evidence and 
provide recommendations for health professionals to enable appropriate clinical decisions.4-7) 
Recognition and application of guidelines are important factors for clinicians because 
medical treatments following such guidelines help reduce mortality rates during in-hospital 
and long-term follow-up periods.8)9)
However, there are some limitations and difficulties for the application of ESC and ACC/AHA 
guidelines to current clinical practices for treating Korean patients with AMI. First, most 
randomized studies on the pharmacotherapy of AMI were performed in the pre-percutaneous 
coronary intervention (PCI) era. Second, several drugs such as cangrelor and bivalirudin are 
not currently available in Korea. Third, there are some concerns about ethnic differences 
in pharmacologic responses.10) Therefore, members of the Task Force on Korean Society of 
Myocardial Infarction reviewed studies performed in Korea during the current PCI era, and 
have summarized the expert consensus on the pharmacotherapy of AMI.
FIBRINOLYSIS IN ST-SEGMENT ELEVATION MYOCARDIAL 
INFARCTION
Summary of the major guidelines and recent publications
Early restoration of an effective forward coronary flow by reperfusion therapy reduces the 
incidences of myocardial damage, ischemic heart failure, and cardiac death. Reperfusion 
therapy includes pharmacologic fibrinolysis and invasive primary PCI in patients with ST-
segment elevation myocardial infarction (STEMI). Primary PCI is preferred over fibrinolysis 
as a reperfusion therapy, because it is superior in terms of reducing death, reinfarction, 
and stroke if the delay in treatment is similar.11-13) However, the advantages of primary PCI 
over fibrinolysis diminish in proportion to PCI-related time delays. ACC/AHA and ESC 
guidelines set time limits for action plans.6)7) If patients with ST-segment elevation on 
electrocardiography are admitted to a non-PCI-capable center, fibrinolysis is recommended 
within 10 minutes when cases meet the following circumstances: 1) onset of ischemic 
symptoms within the previous 12 hours; 2) primary PCI cannot be performed within 2 
hours; and 3) there are no contraindications for fibrinolysis. A fibrin-specific agent such 
as tenecteplase, alteplase, or reteplase is recommended for improving the prognosis.6)14) 
Transfer to a PCI-capable center is recommended for all patients after fibrinolysis for rescue 
(in case of failed fibrinolysis) or elective PCI (in case of successful fibrinolysis) (Table 1).
Adjuvant pharmacotherapy is beneficial for reducing adverse cardiovascular events and 
mortality rates in patients treated with fibrinolysis. Aspirin and clopidogrel should be 
added to fibrinolysis to reduce adverse vascular events.15-17) There is no evidence for using 
glycoprotein (GP) type IIb/IIIa inhibitors or potent P2Y12 receptor inhibitors such as ticagrelor 
and prasugrel.6) Parenteral anticoagulation co-therapy with fibrinolysis is also recommended 
to be administered until PCI can be accomplished, or from at least 48 hours up to 8 days 
846https://e-kcj.org https://doi.org/10.4070/kcj.2020.0196
Expert Consensus Document of Pharmacotherapy of AMI
for medically treated patients with AMI. Enoxaparin and weight-adjusted unfractionated 
heparin are widely used in Korea. The net clinical benefit favored enoxaparin, but the risk of 
non-cerebral bleeding complications was increased in those treated with enoxaparin.18)19) The 
dosage of fibrinolytic and adjunctive antithrombotic agents should be adjusted according to 
the patient's age and renal clearance (Table 2).6)20)21)
Evidence from Korea
The pharmaco-invasive strategy is defined as fibrinolysis combined with rescue PCI or 
routine elective PCI. Currently, more than 90% of patients with AMI undergo primary 
PCI in Korea, and most patients receiving fibrinolysis are transferred to a primary PCI 
center. Therefore, a pharmaco-invasive strategy could be a useful option for reducing the 
total ischemic time in Korean patients. In the Korea Acute Myocardial Infarction Registry 
(KAMIR) data, early elective PCI at less than 24 or 48 hours after successful fibrinolysis 
reduced major adverse cardiac events during a 1-year follow-up.22) As with the Strategic 
Reperfusion Early after Myocardial Infarction (STREAM) study,20) pre-PCI antegrade flow of 
culprit epicardial artery was better in a pharmaco-invasive group.23) However, this advantage 
was not translated into better 1-year clinical outcomes.21)23) In the Comparison of Primary 
Angioplasty and Pre-hospital Fibrinolysis in Acute Myocardial Infarction (CAPTIM) trial, 
early presentation (treated within 2 hours) was associated with lower mortality rates when 
using a pharmaco-invasive strategy than primary PCI in the longer term (5-year) follow-up.24) 
Therefore, it is necessary to wait for more long-term follow-up data for such pharmaco-
invasive strategies for patients with AMI.
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Table 1. Fibrinolysis for ST-segment elevation myocardial infarction
In non-PCI capable center (transfer all patients after or without fibrinolysis)
Fibrinolysis is recommended when meet all 3 criteria
1. Ischemic symptom within 12 hours
2. Primary PCI cannot be performed within 2 hours
3. No contraindications for fibrinolysis
Absolute
- Previous intracranial hemorrhage or stroke of unknown origin at anytime
- Ischemic stroke in the preceding 6 months (except acute stroke within 4.5 hours)
- Central nervous system damage or neoplasm or arteriovenous malformation
- Recent major trauma/surgery/head injury (within the preceding month)
- Gastrointestinal bleeding within the past month
- Known bleeding disorder (excluding menses)
- Aortic dissection
- Non-compressible puncture in the past 24 hours (e.g. liver biopsy, lumbar puncture)
- For streptokinase, prior treatment within the 6 months
Relative
- Transient ischemic attack in the preceding 6 months
- Oral anticoagulant therapy
- Pregnancy or within 1 week postpartum
- Refractory hypertension (SBP >180 mmHg and/or DBP >110 mmHg)
- Advanced liver disease
- Infective endocarditis
- Active peptic ulcer
- Prolonged or traumatic resuscitation
In PCI capable center after fibrinolysis
Emergent angiography (failed fibrinolysis)
1. <50% ST-segment resolution at 60–90 minutes after fibrinolysis
2. Hemodynamic or electrical instability
3. Worsening or recurred ischemia
Elective angiography (2–24 hours after successful fibrinolysis)
DBP = diastolic blood pressure; PCI = percutaneous coronary intervention; SBP = systolic blood pressure.
Recommendations
•  Fibrinolysis should be considered when primary PCI cannot be performed within 2 hours 
and ischemic symptoms appear within 12 hours.
•  A fibrin-specific agent such as tenecteplase, alteplase, or reteplase is recommended. Co-
therapy with dual antiplatelet agents and anticoagulants is also recommended. Dosages 
of these drugs should be adjusted according to the patient's age and creatinine clearance.
•  Immediate transfer to a PCI-capable center is recommended in all patients after fibrinolysis. 
In PCI-capable center, emergency angiography is recommended in the presence of 
hemodynamic or electrical instability, and ischemic signs, and also in cases of failed 
fibrinolysis. Elective angiography is recommended at 2–24 hours after successful fibrinolysis.
BETA-BLOCKER THERAPY IN ACUTE MYOCARDIAL 
INFARCTION
Summary of the major guidelines and recent publications
Beta-blockers are the standard medications for patients with AMI based on evidence from the 
pre-thrombolytic era. The ClOpidogrel and Metoprolol in Myocardial Infarction (COMMIT) 
trial evaluated the effect of early intravenous (IV) and then oral metoprolol in over 40,000 
patients with AMI, and half of the patients received fibrinolysis.25) Metoprolol lowered the 
rate of recurrent MI and ventricular fibrillation but increased the cardiogenic shock, reducing 
the clinical benefit. However, a meta-analysis of randomized controlled trials (RCTs) of 
patients with acute coronary syndrome (ACS) suggested the positive effect of early IV beta-
blockers.26) For patients undergoing primary PCI, early IV metoprolol reduced infarct size, 
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Table 2. Dosage of fibrinolytic and adjunctive antithrombotic agents
Drug Standard dosage Comments
Fibrinolytic agents
Tenecteplase Single IV weight-based bolus Fibrin specificity: strongest
30 mg <60 kg Patency rate 85%
35 mg (7,000 IU) 60–69 kg Age ≥75 years: 50% dose reduction
40 mg 70–79 kg
45 mg (9,000 IU) 80–89 kg
50 mg ≥90 kg
Reteplase 10 units+10 units Fibrin specificity: less strong
IV over 2 minutes (30 minutes apart) Patency rate 84%
Alteplase 15 mg IV bolus 1–2 minutes Fibrin specificity: less strong
0.75 mg/kg over 30 minutes Patency rate 73–84%
0.5 mg/kg over 60 minutes Body weight >67 kg, 15 mg IV bolus, 50 mg over 30 minutes, 35 mg 
over 60 minutes
Antiplatelet agents
Aspirin 150–300 mg loading, 75–100 mg maintain
Clopidogrel 300 mg loading, 75 mg maintain Age ≥75 years
No loading, 75 mg maintain
Anticoagulation
Enoxaparin 30 mg IV bolus Age ≥75 years
1 mg/kg SC every 12 hours  
(maximum 100 mg for the first 2 doses)
No bolus, 25% dose reduction
eGFR <30 mL/min/1.73m2
1 mg/kg every 24 hours
UFH 60 IU/kg IV bolus (maximum 4,000 units) No planned reperfusion
12 IU/kg/hr (maximum 1,000 units/hr) 50–70 IU/kg IV bolus (maximum 5,000 IU)
Target aPTT 1.5–2 times  
(approximately 50–70 seconds)
12 IU/kg/hr
Target aPTT 1.5–2 times (approximately 50–70 seconds)
aPTT = activated partial thromboplastin time; eGFR = estimated glomerular filtration rate; IU = international units; IV = intravenous; SC = subcutaneous; UFH = 
unfractionated heparin.
improved ejection fraction, and also reduced the incidence of major adverse cardiac events 
(MACE) in patients with anterior wall MI.27)28) However, metoprolol therapy failed to reduce 
the infarct size in another study enrolling all patients with STEMI, including those with non-
anterior wall MI.29) A large-scale RCT to define the role of beta-blockers is needed in patients 
with STEMI treated by primary PCI. Oral beta-blockers should be initiated in the first 24 
hours in the latest ACC/AHA guideline. Therapy with IV beta-blockers is recommended only 
in patients with STEMI with ongoing ischemia as Class IIa and evidence level B and is not 
recommended in cases of non-ST segment elevation myocardial infarction (NSTEMI). In the 
ESC guideline, an early beta-blocker is recommended in patients with NSTEMI with ongoing 
ischemia and without contraindications, and is also recommended in STEMI patients before 
primary PCI if the patients are stable.
Regarding the mid and long-term effect of beta-blockers, old studies suggested beta-blockers 
might have significant benefits for patient mortality after MI. However, those studies were 
done in the pre-PCI era, and such beneficial effect of beta-blockers was pronounced in 
patients with heart failure (HF) or ventricular arrhythmia after MI. The Carvedilol Post-
Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) study was the only 
RCT showing long-term benefits of beta-blockers for patients with AMI with reperfusion 
therapy.30) Patients of the CAPRICORN study had left ventricular ejection fraction (LVEF) 
≤40%, were treated with an angiotensin converting enzyme (ACE) inhibitor, and half of the 
patients received reperfusion therapy. Carvedilol reduced all-cause mortality by 23% and all 
the other cardiac events. Recent articles using big data demonstrated no mortality benefits 
in patients aged >65 years and who survived >6 months after MI31) and in patients without 
HF after MI.32) However, many important confounding factors such as sex, and the location 
of infarction limit the interpretation of observational studies of beta-blockers.33) In the 
ACC/AHA guideline, a beta-blocker is recommended in patients with STEMI and NSTEMI 
regardless of ventricular function after discharge, but without mentioning the duration of 
administration. In the ESC guideline, Class IB in patients with NSTEMI, Class IA in patients 
with STEMI with HF, and Class IIa and evidence level B in all cases of STEMI regardless of HF 
are recommended without defining the duration of treatment.
Evidence from Korea
In a Korean observational study that recruited 3,019 PCI-treated patients with AMI with an 
LVEF ≥50%, the use of beta-blocker was associated with lower incidence of all-cause and 
cardiac deaths in patients with AMI during the 3 years of follow-up (hazard ratio [HR], 0.58; 
95% confidence interval [CI], 0.38–0.87 and HR, 0.38; 95% CI, 0.22–0.66, respectively). 
However, the incidence of MI (HR, 1.10; 95% CI, 0.45–2.69) and stroke (HR, 0.59; 95% CI, 
0.26–1.35) were not significantly different between groups.34) Yang et al.35) used KAMIR data 
to identify 8,510 patients with STEMI who underwent primary PCI, and were discharged from 
hospital. Using a 2:1 propensity score-matching process for patients on a beta-blocker, 3,975 
patients were included in the final analysis. After a median follow-up of approximately 1 year, 
the rate of death from any cause was lower in patients on beta-blocker therapy (adjusted HR, 
0.46; 95% CI, 0.27–0.78). However, the subgroup of 3,073 patients (77%) with an LVEF >40% 
demonstrated no significant difference in the rate of all-cause death (unadjusted HR, 0.56; 
95% CI, 0.29–1.07).35) Park et al enrolled all consecutive patients who presented with AMI 
in a single center. They evaluated all-cause mortality at 1, 3, and 5 years after AMI. Of 2,592 
patients, the prescription rates of beta-blockers were 72%, 69%, 63%, and 60% at discharge 
and 1, 3, and 5 years after AMI, respectively. The patients who were receiving beta-blocker 
therapy were younger (62 vs. 65 years; p<0.001) and more likely to receive reperfusion therapy 
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more often (92% vs. 80%; p<0.001) than those without beta-blocker prescriptions. The beta-
blocker prescription at discharge was associated with a 29% reduced mortality risk (HR, 0.71; 
95% CI, 0.55–0.90; p=0.006); however, beta-blocker prescriptions at 1 and 3 years after acute 
MI were not associated with reduced mortality.36)
The beta-blocker has been the state-of-the-art therapy for AMI based on survival benefits 
in studies conducted from the 1980s to 2000s. Changes in the treatment of such patients 
(higher rate of PCI and reperfusion rate and introduction of other potent medications 
including high-intensity statins, dual antiplatelet therapy, and RAAS inhibitors) call for a re-
evaluation of the role of beta-blockers in patients with AMI. The conclusions obtained from 
contemporary observational studies using clinically available data tend to contradict older 
RCTs. However, there have been no RCTs aiming to define the role of beta-blocker therapy 
in patients with AMI. Early beta-blocker therapy might have had benefits such as reducing 
infarct size and the occurrences of ventricular arrhythmia, improvements in left ventricular 
(LV) function and patient survival but also have a risk of shock and unexpected death. In 
patients with HF (LVEF ≤40%), long-term beta-blocker treatment appears reasonable 
considering previous studies. However, the benefit of long-term beta-blocker therapy is 
controversial in patients without HF.
Recommendations
•  Early beta-blocker therapy is recommended for patients with AMI irrespective of the 
revascularization status who do not have contraindication for its use (signs of HF, 
evidence of a low output state, cardiogenic shock, PR interval >0.24 seconds, second- or 
third-degree heart block, active asthma, or reactive airway disease).
•  Long-term oral beta-blockers are indicated in patients with HF and/or LVEF ≤40% unless 
contraindicated.
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
INHIBITORS IN ACUTE MYOCARDIAL INFARCTION
Summary of the major guidelines and recent publications
ACC/AHA guidelines recommend that an ACE inhibitor should be administered within the 
first 24 hours to all patients with STEMI with anterior location, HF, or LVEF ≤40%, unless 
contraindicated (Class I with level of evidence A).7) An angiotensin receptor blocker (ARB) 
should be given to patients with STEMI who have indications for, but are intolerant of, 
ACE inhibitors (Class I with level of evidence B). They also recommend that the use of ACE 
inhibitors is reasonable for all patients with STEMI and no contraindications to their use as 
Class IIa with level of evidence A. In patients with non-ST elevation acute coronary syndrome 
(NSTE-ACS), Class I recommendations are essentially identical to those for patients with 
STEMI. However, the ACC/AHA guidelines for patients with NSTE-ACS recommend that ARBs 
are reasonable in patients without Class I indications who are ACE inhibitor intolerant, as for 
Class IIa with level of evidence B and that the use of ACE inhibitors might be reasonable in all 
other patients with cardiac or other vascular disease as Class IIb with level of evidence B.5)
In general, the ESC guidelines are similar to the ACC/AHA guidelines, but there are subtle 
differences between the two major guidelines. The ESC guideline recommends that ACE 
inhibitors should be started within the first 24 hours of STEMI in patients with evidence of 
HF, LV systolic dysfunction, diabetes, or an anterior infarct as Class I with level of evidence 
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A.6) An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with HF and/
or LV systolic dysfunction, particularly those who are intolerant of ACE inhibitors (Class I 
with level of evidence B). They also recommend that ACE inhibitors should be considered 
in all patients in the absence of contraindications as Class IIa with level of evidence A. For 
patients with NSTE-ACS, the ESC guideline recommends the use of an ACE inhibitor in 
patients with LVEF ≤40% or HF, hypertension or diabetes, unless contraindicated and an 
ARB as an alternative, particularly if ACE inhibitors are not tolerated (Class I with level of 
evidence A).4) However, they do not make any comment on patients without LV systolic 
dysfunction or HF.
The ACC/AHA guidelines recommend therapy with an aldosterone receptor blocker in 
patients after AMI who are without significant renal dysfunction (serum creatinine level >2.5 
mg/dL in men or >2.0 mg/dL in women) or hyperkalemia (K >5.0 mEq/L) and are receiving 
therapeutic doses of ACE inhibitors and beta-blockers and have LVEF ≤40% and HF or 
diabetes mellitus. The recommendations of the ESC guidelines are similar to those of the 
ACC/AHA guidelines.
Evidence from Korea
Several observational studies compared ACE inhibitors and ARBs using data from the 
KAMIR, but the results were inconsistent.37-42) Yang et al.37) reported that the risk of cardiac 
death or recurrent MI in patients with STEMI with preserved LV systolic function was similar 
in patients treated with ACE inhibitors and ARBs and lower than in those who receive 
no RAAS inhibitors. However, another study reported that the use of ACE inhibitors was 
associated with long-term survival benefits compared with ARBs in patients with AMI.42) 
Inclusion of patients with NSTE-ACS or LV systolic dysfunction, reperfusion strategy, and 
different end points might explain the inconsistency of results across previous studies. So far, 
there has been no RCT comparing ACE inhibitors and ARBs for Korean patients.
Data regarding the appropriate type and dose of RAAS inhibitors are very limited. One study 
compared insurmountable ARBs with surmountable ARBs and the former was associated 
with a reduced risk of a composite of cardiac death, nonfatal MI, and revascularization 
compared with the latter.43) In the Valsartan in Post-MI Remodeling (VALID) trial, the 
researchers investigated whether the recommended maximal tolerated dose of valsartan (320 
mg/day or the maximum tolerated daily dose) was more efficacious than the low dose (80 
mg/day) in retarding post-MI LV remodeling in 495 Korean patients with STEMI and LVEF 
≤50%.44) In the VALID trial, treatment with the maximal tolerated dose of valsartan did not 
improve post-MI LV remodeling but caused adverse effects more frequently compared with 
low-dose treatment in Korean patients.
One observational study sought to investigate the effects of the aldosterone receptor blocker, 
spironolactone, on 1-year clinical outcomes in all-comer patients with AMI undergoing PCI.45) 
Spironolactone therapy was associated with a reduced risk of repeat revascularization after 
AMI in patients undergoing PCI. However, RCTs are needed to clarify the possible benefit of 
aldosterone receptor blockers in patients without LV systolic dysfunction or HF.
Recommendations
•  ACE inhibitors are recommended for patients with AMI who have evidence of HF, LVEF 
≤40%, or an anterior infarct.
•  ARBs are alternatives to ACE inhibitors in patients AMI with HF or LVEF ≤40% or an 
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anterior infarct, particularly those who are intolerant of ACE inhibitors.
•  ACE inhibitors should be considered in all patients with STEMI in the absence of 
contraindications.
•  Aldosterone receptor blockers are recommended in patients with an LVEF ≤40% and HF 
or diabetes, who are already receiving an ACE inhibitor and a beta-blocker, provided there 
is no renal failure or hyperkalemia.
ANTIPLATELET THERAPY FOR ACUTE MYOCARDIAL 
INFARCTION
Summary of the major guidelines and recent publications
Platelet activation as well as the coagulation cascade and inflammation play a crucial role in 
the initiation and evolution of an AMI event. Therefore, fast and sufficient platelet inhibition 
is essential among patients with AMI, especially during the early phase after PCI.
NSTEMI: peri-interventional treatment
Aspirin is recommended for all patients without contraindications at an initial oral loading 
dose of 150–300 mg, and at a maintenance dose of 75–100 mg daily long-term. In addition, 
dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 receptor inhibitor (prasugrel 
or ticagrelor) is recommended. Clopidogrel should be permitted only when prasugrel or 
ticagrelor are not available or are contraindicated.
It is not recommended that prasugrel is administered in patients in whom coronary anatomy 
is not known. Because loading with ticagrelor was associated with an early benefit over 
clopidogrel, pre-treatment with ticagrelor can be used in these patients. The Intracoronary 
Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 
(ISAR-REACT 5) trial randomized patients with ACS (ACS=4,018, NSTEMI=1,855) into 
ticagrelor strategy (a loading dose of 180 mg as soon as possible and continued on 90 mg 
twice daily) or prasugrel strategy (a loading dose of 60 mg after coronary angiography/before 
PCI and continued on 10 mg daily: 5 mg daily for those aged ≥75 years or weight <60 kg).46) 
A composite of death, MI, or stroke was more frequently observed in patients receiving 
ticagrelor compared with prasugrel (HR, 1.36, 95% CI, 0.97–1.90), without any difference in 
the risk of major bleeding.
There is a lack of evidence for any clinical benefit in the routine upstream use of GP IIb/IIIa 
inhibitors in patients with NSTEMI planned for coronary angiography and receiving DAPT. In 
the setting of potent P2Y12 receptor inhibitor, where randomized data on GP IIb/IIIa inhibitor 
use has been limited, routine use of GP IIb/IIIa inhibitors cannot be recommended. However, 
this regimen should be considered for bailout situations or thrombotic complications (e.g., 
no-flow, large burden of thrombus), and might be applicable before PCI in patients with 
NSTEMI without pre-treatment with P2Y12 receptor inhibitors. The large-scale evidence 
regarding cangrelor suggests clinical benefits independent of index clinical presentation. 
Therefore, cangrelor might be considered in specific or high-risk settings in P2Y12-naïve 
patients undergoing PCI.4)5)47)
STEMI: peri-interventional treatment
Patients with STEMI undergoing primary PCI should receive aspirin and a P2Y12 receptor 
inhibitor as soon as the diagnosis of STEMI is established. In line with the recommendations 
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for patients with NSTEMI, DAPT is the cornerstone of treatment and consists of aspirin and a 
potent P2Y12 receptor inhibitor. When a potent P2Y12 receptor inhibitor is contraindicated or 
is not available, clopidogrel may be given for primary PCI instead.
Randomized data regarding the clinical benefit of ticagrelor vs. prasugrel in patients with 
STEMI are limited. The Comparison of Prasugrel and Ticagrelor in the Treatment of Acute 
Myocardial Infarction (PRAGUE-18) trial with limited statistical power found similar safety 
and efficacy profiles of ticagrelor and prasugrel in a setting of primary PCI.48) The ISAR-
REACT 5 trial (ACS=4,018, STEMI=1,653) randomized patients with STEMI into ticagrelor 
strategy or prasugrel strategy. The risk of death, MI, or stroke was higher in patients on 
ticagrelor compared with prasugrel (HR, 1.31; 95% CI, 0.94–1.81), without any significant 
difference in the risk of major bleeding.46)
GP IIb/IIIa inhibitors remain a considerable option as bailout therapy or in cases of high-risk 
PCI without pre-treatment with P2Y12 receptor inhibitors. In addition, cangrelor can be used 
in specific settings in P2Y12-naïve patients undergoing PCI.6)7)
AMI: maintenance treatment
Following PCI for AMI, DAPT consisting of a P2Y12 receptor inhibitor in addition to aspirin is 
generally recommended for 12 months. Furthermore, switching or de-escalation strategy of 
DAPT has been a topic of ongoing RCTs. The Anti-Xa Therapy to Lower cardiovascular events 
in Addition to Standard therapy in subjects with Acute Coronary Syndrome–Thrombolysis In 
Myocardial Infarction 51 (ATLAS-ACS 2–TIMI 51) trial (n=15,526) demonstrated that vascular-
dose rivaroxaban (e.g., 2.5 mg twice daily) could be considered for patients without prior 
stroke, and at high ischemic risk and low bleeding risk, receiving aspirin and clopidogrel in 
patients with ACS.49)
In specific clinical scenarios, this standard DAPT duration can be shortened (e.g., 6 months 
in high-bleeding risk patients: PRECISE-DAPT ≥25) or extended (>12 months). Following 
DAPT, lifelong single antiplatelet therapy usually with aspirin is recommended and patients 
should be advised not to discontinue their antiplatelet regimen prematurely after AMI. 
However, in patients with high ischemic risk and without a high bleeding risk, adding 
a second antithrombotic drug to aspirin for long-term secondary prevention should be 
considered. Post-MI patients who have tolerated DAPT for 1 year with high ischemic risk 
(e.g., multi-vessel disease, diabetes mellitus, peripheral artery disease or HF) can be treated 
with long-term DAPT regimens to prevent recurrent MI.50)51)
Evidence from Korea
An increasing body of evidence suggests that East Asian patients have different risk-benefit 
ratio compared with Caucasian patients (Figure 1).10)52)53) Generally, East Asian patients have 
shown a lower risk of atherothrombotic events, and especially in coronary artery diseases. 
In addition, there are emerging concerns in this ethnic group regarding the increased risk 
of gastrointestinal bleeding and hemorrhagic stroke during antiplatelet treatment. This 
phenomenon has been partly explained with their different range in therapeutic window of 
platelet reactivity (the so-called “East Asian Paradox”).
A subgroup analysis enrolling East Asian patients with ACS from RCTs provided important 
insight for this issue (Figure 2). Compared with standard-dose clopidogrel, moderate-
intensity antiplatelet regimens (doubling clopidogrel, adjunctive cilostazol to DAPT and 
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Figure 1. Unique ischemic and bleeding tendency and pharmacokinetics of P2Y12 receptor inhibitors in East Asian population. This figure was modified from the 
original version.53) 





























































Figure 2. Subgroup analyses of East Asians from randomized control trials about acute coronary syndrome. This figure was modified from the original version.53) 
ACS = acute coronary syndrome; AMI = acute myocardial infarction; CI = confidence interval; DAPT = dual antiplatelet therapy; HR = hazard ratio; COMMIT/
CCS-2 = Clopidogrel and Metoprolol in Myocardial Infarction Trial/Second Chinese Cardiac Study; CURRENT/OASIS-7 = Clopidogrel Optimal Loading Dose Usage 
to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS-7; PCI = percutaneous coronary intervention; PHILO = Study to Assess Safety and 
Efficacy of Ticagrelor Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndrome; PRASFIT-ACS = PRASugrel compared 
with clopidogrel For Japanese patIenTs with ACS undergoing PCI; STEMI = ST segment elevation myocardial infarction; TRILOGY-ACS = TaRgeted platelet 
Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes.
low-dose prasugrel therapy of 3.75 mg daily) showed an overall trend toward better clinical 
outcomes, whereas high-intensity antiplatelet regimens (standard-dose prasugrel of 10 mg 
daily and standard-dose ticagrelor of 90 mg twice daily) showed a trend for worse clinical 
outcomes. In Korean patients with AMI, potent antiplatelet regimens have shown the unique 
profile of efficacy and safety compared with DAPT with clopidogrel.52)53) In patients with 
STEMI undergoing primary PCI (n=4,203), triple antiplatelet therapy (TAPT; aspirin plus 
clopidogrel plus cilostazol) showed significantly lower incidences of cardiac death (adjusted 
odds ratio [OR], 0.52; 95% CI, 0.32–0.84; p=0.007), and total MACEs (adjusted OR, 0.74; 
95% CI, 0.58–0.95; p=0.019) at 8 months than DAPT (aspirin plus clopidogrel).54) Older 
(>65 years old), female, and diabetic patients received more benefits from TAPT than from 
DAPT. Compared with DAPT, TAPT had a similar incidence of major bleeding events. DAPT 
with a potent P2Y12 receptor inhibitor has shown the limited benefit for ischemic events and 
increased risk of major bleeding compared with DAPT with clopidogrel. After propensity 
score-matching (1,377 pairs) from the KAMIR-National Institute of Health (NIH) registry, the 
incidences of in-hospital TIMI major and minor bleeding were higher with ticagrelor than 
with clopidogrel (2.6% vs. 1.2%, p=0.008; 3.8% vs. 2.5%, p=0.051, respectively).55) In-hospital 
mortality was higher in patients with than those without TIMI major bleeding (11.3% vs. 0.9%, 
p<0.001). A higher risk for in-hospital TIMI major bleeding with ticagrelor was observed in 
patients aged ≥75 years or with body weight <60 kg (OR, 3.21; 95% CI, 1.36–7.59) and in those 
receiving transfemoral intervention (OR, 2.00; 95% CI, 1.06–3.75). Analysis from KAMIR-NIH 
has shown that potent P2Y12 receptor inhibitors vs. clopidogrel provided a similar prevalence of 
ischemic events and increased risk of serious bleeding in patients with AMI.55-57)
The clinical benefit of potent P2Y12 receptor inhibitors over clopidogrel can be different 
according to the ischemic and bleeding risk profiles. The KAMIR-NIH DAPT score was 
developed and is applicable to guide the selection of P2Y12 receptor inhibitor by evaluating 
combined ischemic (cardiac death, MI, and stent thrombosis) and bleeding (Bleeding 
Academic Research Consortium [BARC] 2, 3 and 5) endpoints during 12 months (Figure 3).  
The patients (n=10,687) were divided into three groups based on the distribution of the 
derived cohort by score: ≤−2 points for the low-score group (16.5%); −1 to 2 points for the 
intermediate-score group (65.7%); ≥3 points for the high-score group (17.8%). Among 
855https://e-kcj.org https://doi.org/10.4070/kcj.2020.0196













−6 to 12Total score:
aAnemia was defined as hemoglobin <13 g/dL for male and <12 g/dL for female
















Figure 3. Scoring system for predicting overall benefit from the use of potent P2Y12 receptor inhibitors. This figure was modified from the original version.58) 
Cr = serum creatinine; LVEF = left ventricular ejection fraction; MI = myocardial infarction; STEMI = ST segment elevation myocardial infarction.
the low-score group, the observed bleeding risk (8.7% vs. 4.4%, p<0.001) on potent P2Y12 
receptor inhibitors vs. clopidogrel exceeded the ischemic benefit (1.3% vs. 2.2%, p=0.185). 
Conversely, the high-score group showed an overall benefit from taking potent P2Y12 
receptor inhibitors vs. clopidogrel from the standpoint of observed ischemic (8.6% vs. 17.1%, 
p<0.001) and bleeding events (10.1% vs. 6.8%, p=0.073).58) Another nationwide population-
based cohort study (70,715 patients with ACS) showed similar results.59) In a propensity-
matched cohort, compared with clopidogrel, prasugrel was associated with a higher risk of 
major bleeding (HR, 1.50; 95% CI, 1.01–2.21) but a similar risk for effectiveness outcomes. 
In addition, ticagrelor was associated with a higher risk of any bleeding (HR, 1.23; 95% 
CI, 1.14–1.33) but a lower risk of mortality (HR, 0.76; 95% CI, 0.63–0.91). No significant 
difference was observed between ticagrelor and prasugrel with respect to major safety and 
effectiveness outcomes. In the randomized Ticagrelor Versus Clopidogrel in Asian/Korean 
Patients with ACS Intended for Invasive Management (TICA-KOREA) trial (n=800), the 
incidence of clinically significant bleeding (PLATO major or minor bleeding) at 12 months 
was significantly higher in the ticagrelor compared with clopidogrel group (11.7% vs. 5.3%, 
HR, 2.26; 95% CI, 1.34–3.79; p=0.002). The incidence of cardiovascular (CV) death, MI, or 
stroke was not significantly different between the ticagrelor and clopidogrel groups (9.2% vs. 
5.8%, HR, 1.62; 95% CI, 0.96–2.74; p=0.07).60)
Several clinical trials from Korea are ongoing or are being conducted to evaluate the efficacy 
and safety of a de-escalation antiplatelet strategy. These dedicated large-scale clinical trials 
could give deep insights into the optimal antiplatelet strategy for the Korean population. 
First, a reduced-dose strategy of potent P2Y12 receptor inhibitor could be considered after the 
acute phase in ACS patients. The Harmonizing optimal strategy for treatment of coronary 
artery diseases–comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in 
ACS patients (HOST-REDUCE-POLYTECH-ACS) trial finished its enrollment to explore the 
optimal maintenance dose of prasugrel beyond 1 month after PCI for ACS in the Korean 
population.61) After the standard dose of prasugrel (10 mg daily) for 1 month post-PCI, 
patients were randomized 1:1 either to the conventional (10 mg daily) or a reduced dose (5 
mg daily). Second, a switching strategy from potent P2Y12 receptor inhibitor to clopidogrel 
could be another approach during the stabilized phase in patients with AMI. The TicAgrelor 
Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) 
trial has also finished its enrollment to compare the clinical efficacy and safety of clopidogrel 
vs. ticagrelor in Korean patients with stabilized MI. Third, another de-escalation strategy 
involves discontinuation of aspirin after the acute phase in patients with ACS. The Ticagrelor 
Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus 
Stent for Acute Coronary Syndrome (TICO) trial finished its enrollment to evaluate the 
clinical outcomes of DAPT with aspirin plus ticagrelor vs. ticagrelor monotherapy from 3 
months post-PCI in patients with ACS. A landmark analysis at 3 months showed that the 
net adverse clinical event rate was 1.4% in the ticagrelor monotherapy group and 3.5% in 
the ticagrelor-based 12-month DAPT group (HR, 0.41; 95% CI, 0.25–0.68; p=0.001). The 
difference between the groups was mainly driven by a reduced risk of major bleeding in the 
ticagrelor monotherapy group (0.2% vs. 1.6%, HR, 0.13; 95% CI, 0.04–0.44; p=0.001).62) 
The Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy 
After DES (SMART-CHOICE) trial compared clinical benefits of aspirin plus a P2Y12 receptor 
inhibitor for 3 months and thereafter P2Y12 receptor inhibitor alone or DAPT for 12 months 
in Korean patients treated with drug-eluting stent (DES) (n=2,993, 58.2% of patients with 
ACS).63) There were no significant differences in all-cause death (1.4% vs. 1.2%, HR, 1.18; 
95% CI, 0.63–2.21; p=0.61), MI (0.8% vs. 1.2%, HR, 0.66; 95% CI, 0.31–1.40, p=0.28), or 
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stroke (0.8% vs. 0.3%, HR, 2.23; 95% CI, 0.78–6.43, p=0.14) between the two groups. 
The rate of bleeding was significantly lower in the P2Y12 receptor inhibitor monotherapy 
group than in the DAPT group (2.0% vs 3.4%, HR, 0.58; 95% CI, 0.36–0.92; p=0.02). This 
study suggested the clinical application of 3-month DAPT and P2Y12 receptor inhibitor 
monotherapy in high bleeding risk patients with low ischemic risk. Finally, a shortened 
duration of DAPT (<12 months) can be a reasonable approach in patients with AMI with low 
ischemic risk or high bleeding risk. The randomized Safety of 6-month Duration of Dual 
Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE) trial enrolled 2,712 
patients with ACS undergoing PCI intervention with DES.64) Six months of DAPT was non-
inferior to 12 months or longer of DAPT for preventing the composite of all-cause death, 
MI or stroke at 18 months (4.7% vs. 4.2%). MI occurred more frequently in the 6-month 
DAPT group than in the 12-month or longer DAPT group (1.8% vs. 0.8%, HR, 2.41; 95% CI, 
1.15–5.05, p=0.02). However, the rate of BARC type 2–5 bleeding was 2.7% in the 6-month 
DAPT group and 3.9% in the 12-month or longer DAPT group (HR, 0.69; 95% CI, 0.45–1.05; 
p=0.09). This observation prevents us from concluding that short-term DAPT is safe in 
patients with ACS treated with current-generation DES.
Clinical evidence regarding adding a second antithrombotic drug to aspirin for long-term 
secondary prevention is still scarce in Korean patients with AMI. The Optimal Duration 
of Clopidogrel Therapy With DES to Reduce Late Coronary Arterial Thrombotic Event 
(DES-LATE) trial (n = 5,045, 61% patients with ACS) randomized DES-treated patients free 
of clinical events to receive aspirin monotherapy or DAPT with clopidogrel for at least 12 
months.65) At 24 months, the composite of CV death, MI or stroke occurred in 2.4% and 
2.6% of the aspirin-monotherapy group and the DAPT therapy group, respectively (HR, 
0.94; 95% CI, 0.66–1.35; p=0.75). Major bleeding was observed in 1.1% and 1.4% of the 
aspirin-monotherapy group and the DAPT therapy group, respectively (HR, 0.71; 95% CI, 
0.42–1.20; p=0.20). From the KAMIR-NIH database, patients who received DAPT beyond 12 
months (n=4,795), compared with patients treated with 12-month DAPT (n=1,404), had a 
similar incidence of MACEs (1.3% vs. 1.0%, HR, 1.32; 95% CI, 0.71–2.45; p=0.378). The two 
groups did not differ significantly in the rates of death (0.1% vs. 0.1%), MI (0.8% vs. 0.6%), 
stent thrombosis (0.1% vs. 0.2%), and ischemic stroke (0.4% vs. 0.2%).66) The Prevention 
of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to 
Placebo on a Background of Aspirin (PEGASUS) trial (n=21,162) demonstrated that 60-mg 
ticagrelor vs. placebo in addition to aspirin reduced the rate of ischemic event (CV death, 
MI or stroke) (7.77% vs. 9.04%, HR, 0.84; 95% CI, 0.74–0.95; p=0.004) and increased the 
rate of TIMI major bleeding (2.30% vs. 1.06%, HR, 2.32; 95% CI, 1.68–3.21; p<0.001) at 3 
years in patients with prior MI (1 to 3 years earlier).67) However, subgroup analysis with Asian 
patients showed no difference in the incidence of ischemic events (7.11% vs. 6.86%) but a 
considerable increase in the number of bleeding episodes (3.74% vs. 1.44%) at 3 years between 
the regimens.68) In addition, the Rivaroxaban for the Prevention of Major Cardiovascular 
Events in Coronary or Peripheral Artery Disease (COMPASS) trial (n=27,395) showed that 
adverse ischemic events (CV death, MI or stroke) occurred in fewer patients in the rivaroxaban-
plus-aspirin group (rivaroxaban 2.5 mg twice daily) than in the aspirin-alone group (4.1% vs. 
5.4%, HR, 0.76; 95% CI, 0.66–0.86; p<0.001), but major bleeding events occurred in more 
patients in the rivaroxaban-plus-aspirin group (3.1% vs. 1.9%, HR, 1.70; 95% CI, 1.40–2.05; 
p<0.001).69) However, the rivaroxaban-plus-aspirin regimen increased major bleeding by 
1.18% in Western populations and 2.13% in Asians, compared with the aspirin-alone group.70) 
Therefore, dedicated trials including Korean patients are needed instead of blind application 
of Western recommendations for antithrombotic therapy in the Korean population.
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A meta-analysis including patients on DAPT (aspirin plus clopidogrel) (n=4,374) reported 
that proton pump inhibitor (PPI) treatment significantly decreased the risk of gastrointestinal 
(GI) bleeding compared with controls (OR, 0.36; 95% CI, 0.15–0.87).71) In addition, there 
was no significant difference in CV adverse events (OR, 1.00; 95% CI, 0.76–1.31). As PPIs 
that inhibit the CYP2C19 pathway can reduce the pharmacodynamic effect of clopidogrel, 
some PPI co-administration (e.g., omeprazole or esomeprazole) with clopidogrel is generally 
not recommended.50) From the Korean nationwide claims data (2007–2015; n=59,233), PPIs 
were associated with increased thrombotic risks (HR, 1.27; 95% CI, 1.12–1.45); PPIs with 
high CYP2C19-inhibitory potential (omeprazole, esomeprazole, and lansoprazole) were 
more relevant than those with low potential (HR, 1.28; 95% CI, 1.02–1.61).72) There were no 
randomized data comparing use vs. non-use of PPIs in patients with coronary artery disease 
receiving prasugrel or ticagrelor in addition to aspirin. However, the risk of GI bleeding 
was higher with DAPT in the form of prasugrel or ticagrelor compared with clopidogrel.50) 
Therefore, co-administration with PPI during DAPT may be mandatory in Korean patients 
with high-risk GI bleeding (such as a history of GI bleeding or peptic ulcer, Helicobacter pylori 
infection, age ≥65 years, concurrent use of anticoagulant, nonsteroidal anti-inflammatory 
drugs [NSAIDs] or steroids, or the use of prasugrel or ticagrelor).
The East Asian population may present a different profile (higher bleeding potential and lower 
ischemic event risk) compared with western population. Emerging evidence from East Asian 
patients have suggested that potent P2Y12 receptor inhibitors exhibit greater antiplatelet effect 
and consequently higher bleeding risk in this population compared with western patients.
Recommendations
•  Use of standard-dose potent P2Y12 receptor inhibitors needs attention regarding the 
increased risk of bleeding especially in Korean patients with bleeding risk factors (e.g. 
prior stroke, old age, low body weight, female gender).
•  Potent P2Y12 receptor inhibitors may be recommended over clopidogrel in the high 
ischemic risk patients with MI undergoing PCI, taking into account the combined 
ischemic and bleeding risks (e.g., KAMIR-NIH DAPT score ≥3 points).
•  After considering the risk-benefit profile, a reduced maintenance dose of potent P2Y12 
receptor inhibitors may be a considerable option for Korean patients with AMI.
•  When discontinuation of a potent P2Y12 receptor inhibitor is required because of 
intolerance (e.g., bleeding or dyspnea), aspirin discontinuation or switching to 
clopidogrel may be a considerable option for Korean patients with ACS.
•  When receiving DAPT in Korean patients, PPIs should be used in patients with a history 
of GI bleeding or peptic ulcer, or in those with risk factors for GI bleeding (Helicobacter 
pylori infection, age ≥65 years, the concomitant use of anticoagulants, NSAIDs or 
steroids, or the use of prasugrel or ticagrelor).
•  The 12-month DAPT is reasonable for Korean patients with AMI. In patients with high 
ischemic risk (e.g., prior MI, diabetes mellitus, chronic kidney disease, multi-vessel 
disease, or complex intervention), prolonged use of DAPT over 12 months may be chosen.
•  Shortened durations of DAPT can be considered for patients with a high risk of bleeding 
or who are intolerant to long-term DAPT treatment, even in a setting of AMI.
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LIPID-LOWERING THERAPY
Summary of the major guidelines and recent publications
A meta-analysis of data from 170,000 participants in 26 randomized trials showed that the 
more intensive use of statins produced greater reductions in coronary death, nonfatal MI, 
ischemic stroke, and coronary revascularization.73) Each 1.0 mmol/L (40 mg/dL) reduction in 
low-density lipoprotein cholesterol (LDL-C) reduced the annual rate of major vascular events 
by just over a fifth. Accordingly, current ACC/AHA and ESC guidelines have stated to start 
high-intensity statin therapy as early as possible after AMI as a Class I recommendation.6)7) 
While the 2013 ACC Foundation/AHA guideline did not refer to a specific goal of LDL-C 
concentrations,7) the 2018 ACC guideline on the management of blood cholesterol adopted 
a recommendation of using a LDL-C threshold of 70 mg/dL in very high-risk patients 
including those with ACS.74) The most recent 2019 ESC guideline for the management of 
dyslipidemia went a step further and recommended reducing the goal of LDL-C level from 
70 to 55 mg/dL in very high-risk patients, including those with MI, based on large-scale RCTs 
using ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.75-78) 
Furthermore, the guideline recommended that for patients with AMI who experience a 
second vascular event within 2 years (not necessarily of the same type as the first event) while 
taking maximally tolerated statin therapy, an LDL-C goal of <40 mg/dL may be considered, 
as Class IIb and with level of evidence B. However, most recent ACC/AHA or ESC guideline-
directed prescription of PCSK9 inhibitors is not fully reimbursed by the Korean Health 
Insurance Review and Assessment Service (HIRA). Thus, we have to adjust two guidelines 
and Korean insurance regulation and keep a balance between them. In addition, there are 
no large-scale data on the association of PCSK9 inhibitors with clinical outcomes in Asian 
patients with very high cardiovascular risks including AMI. For the adoption of the 2019 ESC 
guidelines into Korean real-world practice, we need more data on 1) the efficacy and safety 
of PCSK9 inhibitors on clinical outcome and 2) whether lowering LDL-C levels below 55 mg/
dL would be more beneficial than a LDL target of 70 mg/dL. Meanwhile, 2 of the guidelines 
recommend that a lipid profile should be obtained as early as possible after admission for 
AMI and should be re-evaluated 4–6 weeks after AMI to determine whether the target levels 
have been reached and for evaluating any side effects from statins. The intensity of statin 
therapy should be increased unless there are intolerance and safety issues.
The beneficial impact of statins on clinical outcome has been well established, exerted by 
dual mechanisms including plasma LDL-C lowering and pleiotropic anti-inflammatory 
effects on atherosclerotic plaques.79-81) The Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial (IMPROVE-IT) study is the first trial to show a benefit of adding 
a non-statin lipid-modifying agent to statin therapy.76) Thus, ezetimibe should be given to 
patients when the therapeutic goal is not achieved at the maximally tolerated statin dose or 
when statins are not tolerated because of serious side effects. Two major studies using PCSK9 
inhibitors including evolocumab and alirocumab have shown significant benefits in reducing 
MACEs in patients with LDL-C levels of 70 mg/dL or higher despite maximally tolerated 
statin therapy.77)78) Thus, the large-scale, randomized, controlled studies using ezetimibe 
and two PCSK9 inhibitors has made 2019 ESC lipid guidelines revise the concept of LDL-C 
goals and include non-statin lipid therapy into the guidelines. While the recommendation 
that a high-intensity statin should be prescribed to the highest tolerated dose is still most 
important, ezetimibe and/or PCSK9 inhibitors can be considered in patients not achieving 
their lipid goal.
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Evidence from Korea
The KAMIR data between 2005 and 2007 demonstrated that statin therapy significantly 
reduced the risk of the composite of all cause of death, recurrent MI, target vessel 
revascularization (TVR) and coronary artery bypass graft surgery even in patients with LDL-C 
below 70 mg/dL.82) In addition, further analysis of 1,048 patients with AMI with LDL-C 
<50 mg/dL in the KAMIR registry between 2005 and 2014 revealed statin therapy further 
reduced the risk of MACEs.83) Thus, Korean data strongly support the idea that serum LDL-C 
levels should be reduced as much as possible. Moreover, statin therapy should be given to 
all patients with AMI irrespective of their serum LDL-C levels, if tolerable. The COREA-
AMI registry analyzing 3,921 statin-naïve patients with AMI undergoing PCI demonstrated 
that early statin therapy within 48 hours after admission reduced adverse long-term clinical 
outcomes compared with statin initiation later, which supports the concept that statin 
therapy should be started as soon as possible in patients with AMI.84) In terms of lipid 
therapy, Korean data also support the concepts of the recent ESC and ACC/AHA guidelines. 
However, high-intensity statins are sometimes prescribed to Korean patients with AMI in 
the real world. In the KAMIR data from 2005 to 2014, high-intensity statins were prescribed 
in only 6.8% of patients with AMI undergoing successful PCI (2,271/33,442 patients).85) In 
contrast, low- to moderate-intensity statins were prescribed in more than 75% of patients 
with AMI. Asian patients receive lower doses of statin in most clinical settings compared 
with their Western counterparts.86) In the 2013 ACC/AHA lipid guidelines, Asian ancestry is 
considered as a characteristic that might modify the decision to use high-intensity therapy.87) 
Further studies are needed on the issue of statin intensity in Korean patients with AMI.
Recommendations
•  It is recommended to obtain a lipid profile in all patients with AMI as soon as possible 
after presentation.
•  It is recommended to start high-intensity statin therapy as early as possible after AMI, 
unless contraindicated, and maintain it during the long term.
•  Treatment goals are recommended as an LDL-C reduction of ≥50% from baseline or an 
LDL-C level of <70 mg/dL in patients with AMI.
•  In patients with AMI with LDL-C ≥70 mg/dL despite a maximally tolerated statin dose, 
combination with ezetimibe is recommended.
•  In patients with AMI with LDL-C ≥70 mg/dL despite a maximally tolerated dose of a statin 
and ezetimibe, a combination with a PCSK9 inhibitor is recommended.
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